Successful strategy to improve the specificity of electronic statin-drug interaction alerts

European Journal of Clinical Pharmacology

Volumn 65, Issue 11, 2009, Pages 1149-1157

  Seidling, Hanna Marita ^a   Storch, Caroline Henrike ^a   Bertsche, Thilo ^a   Senger, Christian ^a   Kaltschmidt, Jens ^a   Walter Sack, Ingeborg ^a   Haefeli, Walter Emil ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE   (Germany)

Author keywords

Clinical decision support systems; Drug drug interactions; HMG CoA Reductase inhibitors; Over alerting; Upper dose limits

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; CYP3A4 INDUCTOR; CYP3A4 INHIBITOR; ENZYME INDUCING AGENT; ENZYME INHIBITOR; ERYTHROMYCIN; FLUINDOSTATIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG SAFETY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICAL ORDER ENTRY SYSTEMS; MEDICATION ERRORS; RETROSPECTIVE STUDIES;

EID: 70350221021     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0704-x     Document Type: Article

References (67)

1. GJ Kuperman A Bobb T Payne AJ Avery TK Gandhi G Burns, et al. 2007 Medication-related clinical decision support in computerized provider order entry systems: a review J Am Med Inform Assoc 14 29 40 10.1197/jamia.M2170 17068355 (Pubitemid 44909484)
2. H van der Sijs J Aarts A Vulto M Berg 2006 Overriding of drug safety alerts in computerized physician order entry J Am Med Inform Assoc 13 138 147 10.1197/jamia.M1809 16357358 (Pubitemid 43332904)
3. MD Paterno SM Maviglia PN Gorman DL Seger E Yoshida AC Seger, et al. 2009 Tiering drug-drug interaction alerts by severity increases compliance rates J Am Med Inform Assoc 16 40 46 10.1197/jamia.M2808 18952941
4. JT Backman KT Kivistö KT Olkkola PJ Neuvonen 1998 The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur J Clin Pharmacol 54 53 58 10.1007/s002280050420 1:CAS:528:DyaK1cXhvFCqt7k%3D 9591931 (Pubitemid 28189400)
5. M Ucar T Mjörndal R Dahlqvist 2000 HMG-CoA reductase inhibitors and myotoxicity Drug Saf 22 441 457 10.2165/00002018-200022060-00003 1:CAS:528:DC%2BD3cXkslygsrk%3D 10877038
6. A Thibault D Samid AC Tompkins WD Figg MR Cooper RJ Hohl, et al. 1996 Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 483 491 1:CAS:528:DyaK28XitVymu7o%3D 9816194
7. D Schmassmann-Suhijar R Bullingham R Gasser J Schmutz WE Haefeli 1998 Rhabdomyolysis due to interaction of simvastatin with mibefradil Lancet 351 1929 1930 10.1016/S0140-6736(05)78613-X 1:STN:280:DyaK1czhs1ygtQ%3D%3D 9654265 (Pubitemid 28297454)
8. R Imamura N Ichimaru T Moriyama Y Shi Y Namba N Nonomura, et al. 2005 Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus Clin Transplant 19 616 621 10.1111/j.1399-0012.2005. 00341.x 16146552 (Pubitemid 41341692)
9. JA Kobashigawa FL Murphy LW Stevenson JD Moriguchi N Kawata P Kamjoo, et al. 1990 Low-dose lovastatin safely lowers cholesterol after cardiac transplantation Circulation 82 Suppl 4 281 283
10. C Chen RJ Mireles SD Campbell J Lin JB Mills JJ Xu, et al. 2005 Differential interaction of 3-hydroxy-3-methylglutaryl-CoA-reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab Disp 33 537 546 10.1124/dmd.104.002477 1:CAS:528:DC%2BD2MXjtFCjsrs%3D (Pubitemid 40393197)
11. B Hsiang Y Zhu Z Wang Y Wu V Sasseville WP Yang, et al. 1999 A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J Biol Chem 274 37161 37168 10.1074/jbc.274.52.37161 1:CAS:528:DC%2BD3cXpsFSr 10601278 (Pubitemid 30016792)
12. A Asberg 2003 Interactions between cyclosporin and lipid-lowering drugs Implications for organ transplant recipients. Drugs 63 367 378 1:CAS:528:DC%2BD3sXisVKjtbg%3D
13. MA Omar JP Wilson 2002 FDA adverse event reports on statin-associated rhabdomyolysis Ann Pharmacother 36 288 295 10.1345/aph.1A289 1:CAS:528:DC%2BD38XitFOjtLg%3D 11847951
14. Baxter K (ed) (2007) Stockley's drug interactions, 8th edn. Pharmaceutical Press, Chicago London
15. Lendac Data Systems: DRUGDEX® System (database on CD-ROM). Thomson Healthcare, Greenwood Village
16. JA Tobert 1988 Efficacy and long-term adverse effect pattern of lovastatin Am J Cardiol 62 28J 34J 10.1016/0002-9149(88)90004-5 1:STN:280:DyaL1M%2FkslWltQ%3D%3D 3055921
17. Holdaas H, Felström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al, on behalf of the assessment of LEscol in renal transplantation (ALERT) study investigators 2003 Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 2024 2031 10.1016/S0140-6736(03)13638-0 (Pubitemid 36695044)
18. V Launay-Vachar H Izzedine G Deray 2005 Statins' dosage in patients with renal failure and cyclosporine drug-drug interaction in transplant patients Int J Clin Cardiol 101 9 17 10.1016/j.ijcard.2004.04.005 (Pubitemid 40614730)
19. J Kirchheiner D Kudlicz C Meisel S Bauer I Meineke I Roots, et al. 2003 Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S, 5R-fluvastatin and (+)-3R, 5S-fluvastatin in healthy volunteers Clin Pharmacol Ther 74 186 194 10.1016/S0009-9236(03)00121-8 1:CAS:528:DC%2BD3sXlvVCrtL4%3D 12891229 (Pubitemid 36951816)
20. RJ Höppener A Kuyer JW Meijer J Hulsman 1980 Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects Epilepsia 21 341 350 10.1111/j.1528-1157.1980.tb04081.x 7398602
21. WE Haefeli 2007 Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease J Neurol 254 Suppl 4 IV/29 IV/36 1:CAS:528:DC%2BD2sXhtFGgtbzM
22. A Asberg A Hartmann E Fjeldså S Bergan H Holdaas 2001 Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients Am J Transplant 1 382 386 10.1034/j.1600-6143.2001.10415.x 1:CAS:528:DC%2BD38XisFartw%3D%3D 12099384 (Pubitemid 33681704)
23. M Hermann A Asberg H Christensen H Holdaas A Hartmann JL Reubsaet 2004 Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients Clin Pharmacol Ther 75 101 109 10.1016/j.clpt.2003.11.036
24. WP Lemahieu M Hermann A Asberg K Verbeke H Holdaas Y Vanrenterghem, et al. 2005 Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus Am J Transplant 5 2236 2243 10.1111/j.1600-6143. 2005.01005.x 1:CAS:528:DC%2BD2MXhtVeku7%2FJ 16095503 (Pubitemid 41648471)
25. GW Amsden O Kuye GC Wei 2002 A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers J Clin Pharmacol 42 444 449 10.1177/0091270002424011 1:CAS:528:DC%2BD38Xjt1ynsrg%3D 11936570 (Pubitemid 34259779)
26. TA Jacobson 2004 Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors Am J Cardiol 94 1140 1146 10.1016/j.amjcard.2004.07.080 1:CAS:528:DC%2BD2cXptFOqtb8%3D 15518608 (Pubitemid 39424216)
27. JG Gerber SL Rosenkranz CJ Fichtenbaum JM Vega A Yang BL Alston AIDS Clinical Trials Group A5108 Team, et al. 2005 Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin. Results of AIDS Clinical Trials Group 5108 Study J Acquir Immune Defic Syndr 39 307 312 10.1097/01.qai.0000167156.44980.33 1:CAS:528:DC%2BD2MXlsFantL8%3D 15980690 (Pubitemid 40923210)
28. PH Siedlik SC Olson BB Yang RH Stern 1999 Erythromycin coadministration increases plasma atorvastatin concentrations J Clin Pharmacol 39 501 504 1:CAS:528:DC%2BD3cXivFajsQ%3D%3D 10234598
29. JT Backman H Luurila M Neuvonen PJ Neuvonen 2005 Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites Clin Pharmacol Ther 78 154 167 10.1016/j.clpt.2005.04.007 1:CAS:528:DC%2BD2MXnslyhtLo%3D 16084850 (Pubitemid 41112284)
30. T Kantola KT Kivistö PJ Neuvonen 1998 Effect of itraconazole on the pharmacokinetics of atorvastatin Clin Pharmacol Ther 64 58 65 10.1016/S0009-9236(98)90023-6 1:CAS:528:DyaK1cXltlarsrk%3D 9695720 (Pubitemid 28377331)
31. AL Mazzu KC Lasseter EC Shamblen V Agarwal J Lettieri P Sundaresen 2000 Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin Clin Pharmacol Ther 68 391 400 10.1067/mcp.2000.110537 1:CAS:528:DC%2BD3cXot1Wjtr8%3D 11061579 (Pubitemid 30803528)
32. PH Hsyu MD Schultz-Smith JH Lillibridge RH Lewis BM Kerr 2001 Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin Antimicrob Agents Chemother 45 3445 3450 10.1128/AAC.45.12.3445-3450.2001 1:CAS:528: DC%2BD3MXovVOltrc%3D 11709322 (Pubitemid 33107860)
33. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al, NIAID AIDS Clinical Trials Group 2002 Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 AIDS 16 569 577 10.1097/00002030-200203080-00008 (Pubitemid 34218852)
34. JW Park R Siekmeier P Lattke M Merz C Mix S Schüler, et al. 2001 Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A J Cardiovasc Pharmacol Ther 6 351 361 10.1177/107424840100600404 1:CAS:528:DC%2BD38XitVCrsb0%3D 11907637
35. R Goldberg D Roth 1996 Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine Transplantation 62 1559 1564 10.1097/00007890-199612150-00005 1:CAS:528:DyaK2sXjtVWitg%3D%3D 8970607 (Pubitemid 27009910)
36. T Kantola JT Backman M Niemi KT Kivistö PJ Neuvonen 2000 Effect of fluconazole on plasma fluvastatin and pravastatin concentrations Eur J Clin Pharmacol 56 225 229 10.1007/s002280000127 1:CAS:528:DC%2BD3cXjvFCgsbo%3D 10952477 (Pubitemid 30456682)
37. KT Kivistö T Kantola PJ Neuvonen 1998 Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin Br J Clin Pharmacol 46 49 53 10.1046/j.1365-2125.1998.00034.x 9690949 (Pubitemid 28308424)
38. L Gullestad KP Nordal KJ Berg H Cheng MS Schwartz S Simonsen 1999 Interaction between lovastatin and cyclosporine A after heart and kidney transplantation Transplant Proc 31 2163 2165 10.1016/S0041-1345(99)00295-X 1:CAS:528:DyaK1MXlslKit7w%3D 10456002 (Pubitemid 29376559)
39. C Olbricht C Wanner T Eisenhauer V Kliem R Doll M Boddaert, et al. 1997 Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses Clin Pharmacol Ther 62 311 321 10.1016/S0009-9236(97)90034-5 1:CAS:528:DyaK2sXmslOrtLw%3D 9333107 (Pubitemid 27417797)
40. Bramer SL, Brisson J, Corey AE, Mallikaarjun S (1999) Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Clin Pharmacokinet 37[Suppl 2]:69-77
41. NE Azie DC Brater PA Becker DR Jones SD Hall 1998 The interaction of diltiazem with lovastatin and pravastatin Clin Pharmacol Ther 64 369 377 10.1016/S0009-9236(98)90067-4 1:STN:280:DyaK1M%2FhsVGhtQ%3D%3D 9797793 (Pubitemid 28473762)
42. C Kyrklund JT Backman KT Kivistö M Neuvonen J Laitila PJ Neuvonen 2001 Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin Pharmacol Ther 69 340 345 10.1067/mcp.2001.115542 1:CAS:528:DC%2BD3MXktlyhsL8%3D 11372002 (Pubitemid 32477075)
43. PJ Neuvonen KM Jalava 1996 Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 60 54 61 10.1016/S0009-9236(96)90167-8 1:CAS:528:DyaK28XltFSqu7o%3D 8689812
44. BJ Ring BE Patterson MI Mitchell M Vandenbranden J Gillespie AW Bedding, et al. 2005 Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo Clin Pharmacol Ther 77 63 75 10.1016/j.clpt.2004. 09.006 1:CAS:528:DC%2BD2MXks1Wr 15637532 (Pubitemid 40075390)
45. L Becquemont M Neuvonen C Verstuyft P Jaillon A Letierce PJ Neuvonen C Funck-Brentano 2007 Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics Clin Pharmacol Ther 81 679 684 10.1038/sj.clpt.6100098 1:CAS:528:DC%2BD2sXlsFCqsLs%3D 17301736 (Pubitemid 46625102)
46. JW Park R Siekmeier M Merz B Krell S Harder W März, et al. 2002 Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A Int J Clin Pharmacol Ther 40 439 450 1:CAS:528:DC%2BD38XotlGkur4%3D 12395976
47. MB Regazzi I Iacona C Campana V Raddato C Lesi G Perani, et al. 1993 Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients Transplant Proc 25 2732 2734 1:STN:280:DyaK3szmt1egsw%3D%3D 8356729
48. C Kyrklund JT Backman M Neuvonen PJ Neuvonen 2003 Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin Pharmacol Ther 73 538 544 10.1016/S0009-9236(03)00052-3 1:CAS:528: DC%2BD3sXkt1Ortbo%3D 12811363 (Pubitemid 37249124)
49. PJ Neuvonen T Kantola KT Kivistö 1998 Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 332 341 10.1016/S0009-9236(98)90165-5 1:CAS:528:DyaK1cXisVWnu7o%3D 9542477 (Pubitemid 28182231)
50. JA Aberg SL Rosenkranz CJ Fichtenbaum BL Alston SW Brobst Y Segal ACTG A5108 team, et al. 2006 Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108 AIDS 20 725 729 10.1097/01.aids.0000216373.53819.92 1:CAS:528:DC%2BD28XhvFOmt7c%3D 16514303 (Pubitemid 43884300)
51. C Kyrklund JT Backman M Neuvonen PJ Neuvonen 2003 Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects Br J Clin Pharmacol 57 181 187 10.1046/j.1365-2125.2003.01972.x
52. AJ Busti AM Bain RG Hall 2nd RG Bedimo RD Leff C Meek, et al. 2008 Effects of atazanavir/ritonavir or fosamprenovir/ritonavir on the pharmacokinetics of rosuvastatin J Cardiovasc Pharmacol 51 605 610 10.1097/FJC.0b013e31817b5b5a 1:CAS:528:DC%2BD1cXnslaktr4%3D 18520949
53. SG Simonson A Raza PD Martin PD Mitchell JA Jarcho CD Brown, et al. 2004 Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin Pharmacol Ther 76 176 177 10.1016/j.clpt.2004.03.010 (Pubitemid 39013406)
54. KJ Cooper PD Mertin AL Dane MJ Warwick A Raza DW Schneck 2003 The effect of erythromycin on the pharmacokinetics of rosuvastatin Eur J Clin Pharmacol 59 51 56 1:CAS:528:DC%2BD3sXjslWhsLs%3D 12682802
55. DW Schneck BK Birmingham JA Zalikowski PD Mitchell Y Wang PD Martin, et al. 2004 The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 75 455 463 10.1016/j.clpt.2003.12.014 1:CAS:528: DC%2BD2cXjs1Cjtbs%3D 15116058 (Pubitemid 38534566)
56. KJ Cooper PD Martin AL Dane MJ Warwick DW Schneck MV Cantarini 2003 Effect of itraconazole on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 73 322 329 10.1016/S0009-9236(02)17633-8 1:CAS:528:DC%2BD3sXjtFWntb4%3D 12709722 (Pubitemid 36403592)
57. JJ Kiser JG Gerber JA Predhomme P Wolfe DM Flynn DW Hoody 2008 Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers J Acquir Immune Defic Syndr 47 570 578 10.1097/QAI.0b013e318160a542 1:CAS:528:DC%2BD1cXjs1Gqt7k%3D 18176327
58. S Nishio H Watanabe K Kosuge S Uchida H Hayashi K Ohashi 2005 Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension Hypertens Res 28 223 237 10.1291/hypres.28.223 1:CAS:528: DC%2BD2MXltlCqsrY%3D 16097365 (Pubitemid 40812606)
59. J Dingemanse D Schaarschmidt PLM van Giersbergen 2003 Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin Clin Pharmacokinet 42 293 301 10.2165/00003088-200342030-00004 1:CAS:528:DC%2BD3sXisVOitbw%3D 12603176 (Pubitemid 36308067)
60. N Ichimaru S Takahara Y Kokado JD Wang M Hatori H Kameoka, et al. 2001 Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus Atherosclerosis 158 417 423 10.1016/S0021-9150(01)00438-5 1:CAS:528:DC%2BD3MXnt1Whurw%3D 11583721 (Pubitemid 32913652)
61. M Arnadottir LO Eriksson H Thysell JD Karkas 1993 Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 410 413 10.1159/000187521 1:STN:280:DyaK2c7hvFaqug%3D%3D 8289991
62. H Watanabe K Kosuge S Nishio H Yamada S Uchida H Satoh, et al. 2004 Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension Life Sci 76 281 292 10.1016/j.lfs.2004.06.022 1:CAS:528:DC%2BD2cXpsFWrtbw%3D 15531380 (Pubitemid 39456434)
63. O Mousa DC Brater KJ Sunblad SD Hall 2000 The interaction of diltiazem with simvastatin Clin Pharmacol Ther 67 267 274 10.1067/mcp.2000.104609 1:CAS:528:DC%2BD3cXis1Ghtro%3D 10741630
64. T Kantola KT Kivistö PJ Neuvonen 1998 Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 64 177 182 10.1016/S0009-9236(98)90151-5 1:CAS:528: DyaK1cXlvVyksr4%3D 9728898 (Pubitemid 28423853)
65. JT Backman C Kyrklund KT Kivistö JS Wang PJ Neuvonen 2000 Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin Pharmacol Ther 68 122 129 10.1067/mcp.2000.108507 1:CAS:528:DC%2BD3cXmsFamu7s%3D 10976543 (Pubitemid 30659167)
66. SG O'Brien P Meinhardt E Bond J Beck B Peng C Dutreix, et al. 2003 Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia Br J Cancer 89 1855 1859 10.1038/sj.bjc.6601152 14612892 (Pubitemid 37533259)
67. C Kyrklund JT Backman KT Kivistö M Neuvonen J Laitila PJ Neuvonen 2000 Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 68 592 597 10.1067/mcp.2000.111414 1:CAS:528:DC%2BD3MXht1Sjs7s%3D 11180018 (Pubitemid 32059984)